Germany: SPCs for medical devices

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Germany: SPCs for medical devices

While SPCs can be granted for medicinal products in accordance with Regulation (EC) No 469/2009, it has been questioned whether medical devices that are also subject to a lengthy product approval process similar to medicinal products could be eligible for SPC protection in the absence of an explicit Regulation in this respect. In the past, the German Federal Patent Court (Bundespatentgericht or BPatG) adopted a relatively liberal approach in deciding that SPCs for an implantable medical device comprising a pharmaceutically active substance are allowable (14 W (pat) 12/07). A recent case may signal that the German Federal Patent Court may apply a stricter approach in the future.

The 14th Senate of the BPatG held in decision 14 W (pat) 45/12 that SPCs cannot be granted for medical devices under the Regulation and the corresponding case law of the CJEU. The Leibniz-Institut für Neue Materialien gGmbH filed an SPC application for aminosilane-coated iron oxide nanoparticles, which are directly introduced into a tumour and then heated by the application of an external magnetic field. This treatment results in the destruction or in the sensitisation of the tumour cells for further treatment. The application was based on an EC design-examination certificate in accordance with Directive 93/42/EEC on Medical Devices.

According to Article 1(b) of the Regulation, "product" means the active ingredient or combination of active ingredients of a medicinal product. Since the term "active ingredient" is not defined in the Regulation, the BPatG referred to the CJEU decision Forsgren (C-631/13), which held that active ingredients must have pharmacological, immunological or metabolic action of their own. The BPatG concluded that the therapeutic effect of the aminosilane-coated iron oxide particles, which are inactive on their own, is purely physical, and therefore the particles do not fall under the definition of the term "product" as defined by Article 1(b) of the Regulation, thus ruling out the application of the Regulation.

While the BPatG indicated that it favours the grant of SPCs for medical products, it made clear that it will be up to the legislator to implement corresponding legal frameworks. It remains to be seen whether the recent decision marks a new era of stricter rulings on SPCs to medical devices in Germany, or whether it only precludes the grant of SPCs for medical devices that do not have a therapeutic effect on their own.

Wunsche

Annelie Wünsche


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article